MAUI (MBI Analysis User Interface)-An image processing pipeline for Multiplexed Mass Based Imaging.
Journal
PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
29
06
2020
accepted:
17
03
2021
revised:
29
04
2021
pubmed:
20
4
2021
medline:
15
9
2021
entrez:
19
4
2021
Statut:
epublish
Résumé
Mass Based Imaging (MBI) technologies such as Multiplexed Ion Beam Imaging by time of flight (MIBI-TOF) and Imaging Mass Cytometry (IMC) allow for the simultaneous measurement of the expression levels of 40 or more proteins in biological tissue, providing insight into cellular phenotypes and organization in situ. Imaging artifacts, resulting from the sample, assay or instrumentation complicate downstream analyses and require correction by domain experts. Here, we present MBI Analysis User Interface (MAUI), a series of graphical user interfaces that facilitate this data pre-processing, including the removal of channel crosstalk, noise and antibody aggregates. Our software streamlines these steps and accelerates processing by enabling real-time and interactive parameter tuning across multiple images.
Identifiants
pubmed: 33872301
doi: 10.1371/journal.pcbi.1008887
pii: PCOMPBIOL-D-20-01128
pmc: PMC8084329
doi:
Substances chimiques
Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1008887Subventions
Organisme : NIH HHS
ID : DP5 OD019822
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG056287
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG057915
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA224309
Pays : United States
Organisme : CIHR
Pays : Canada
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: MA is a consultant and shareholder in IonPath.
Références
Nature. 2020 Feb;578(7796):615-620
pubmed: 31959985
Cancer Commun (Lond). 2020 Apr;40(4):135-153
pubmed: 32301585
Science. 2016 Jul 1;353(6294):78-82
pubmed: 27365449
Nat Rev Rheumatol. 2020 Feb;16(2):87-99
pubmed: 31892734
Cell. 2018 Aug 9;174(4):968-981.e15
pubmed: 30078711
Science. 2018 Jul 27;361(6400):
pubmed: 29930089
Science. 2018 Nov 16;362(6416):
pubmed: 30385464
Nat Methods. 2013 Sep;10(9):857-60
pubmed: 23852452
Science. 2018 Aug 3;361(6401):
pubmed: 30072512
Cell. 2018 Sep 6;174(6):1373-1387.e19
pubmed: 30193111
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11982-7
pubmed: 23818604
J Immunother Cancer. 2020 May;8(1):
pubmed: 32414858
Cell Syst. 2018 May 23;6(5):612-620.e5
pubmed: 29605184
Immunity. 2012 Aug 24;37(2):364-76
pubmed: 22863836
Sci Adv. 2019 Oct 09;5(10):eaax5851
pubmed: 31633026
Nat Biotechnol. 2019 Sep;37(9):1080-1090
pubmed: 31427819
Nat Med. 2014 Apr;20(4):436-42
pubmed: 24584119
Nat Biotechnol. 2018 Oct 29;:
pubmed: 30371680